A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease.
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2015
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Schwarz Pharma AG; UCB
- 20 Apr 2015 Post-hoc analysis of pooled data presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), according to a UCB media release.
- 16 Oct 2009 UCB, Inc. added as trial sponsor as reported by ClinicalTrials.gov.
- 16 Oct 2009 Additional locations identified as reported by ClinicalTrials.gov.